Evidence exists for the potential protective effects of circulating ovarian hormones in stroke, and oestrogen reduces brain damage in animal ischaemia models. However, a recent clinical trial indicated that HRT (hormone-replacement therapy) increased the incidence of stroke in postmenopausal women, and detrimental effects of oestrogen on stroke outcome have been identified in a meta-analysis of HRT trials and in pre-clinical research studies. Therefore oestrogen is not an agent that can be promoted as a potential stroke therapy. Many published reviews have reported the neuroprotective effects of oestrogen in stroke, but have failed to include information on the detrimental effects. This issue is addressed in the present review, along with potential mechanisms of action, and the translational capacity of pre-clinical research.
INTRODUCTION
Oestrogen is among the most commonly prescribed drugs due to its use as an oral contraceptive and as HRT (hormone-replacement therapy) for post-menopausal women. HRT is very effective in relieving symptoms associated with oestrogen deficiency, such as vasomotor symptoms (hot flushes and night sweats) and urogenital symptoms (vaginal dryness), as well as disrupted sleep, libido and osteoporosis. Following publication of the results of the widely publicized WHI (Women's Health Initiative) trial [1] , concerns were raised regarding the safety of prolonged oestrogen use in post-menopausal women. This has resulted in a marked decrease in the number of patients taking HRT and increased patient interest in HRT alternatives, such as SERMs (selective oestrogen receptor modulators), phytoestrogens and soya derivatives. The present review covers the evidence in the pre-clinical stroke literature for the beneficial and detrimental influences of oestrogen and oestrogenic compounds, as well as the benefits and costs of HRT in the clinic within the context of stroke, CHD (coronary heart disease) and vascular disease. We aim to discuss the basis for the inconsistencies between clinical and pre-clinical outcomes, and suggest a way forward for research into the effects of oestrogen on stroke.
PRE-CLINICAL STUDIES

Beneficial and detrimental effects of oestrogen alone
The majority of in vivo studies have used rodent stroke models and have indicated that oestrogen is neuroprotective (reviewed in [2] [3] [4] [5] ). Indeed, a systematic review of the experimental literature indicated that oestrogen reduces ischaemic damage induced by permanent or transient MCAO (middle cerebral artery occlusion) in a dose-dependent manner [6] . In addition, female SHRSPs (stroke-prone spontaneously hypertensive rats) receiving a focal ischaemic insult during pro-oestrus (high oestrogen phase of the oestrus cycle) had reduced damage when compared with SHRSPs that received a stroke during metoestrus [7] . The volume of ischaemic damage decreases as the levels of endogenous oestrogen increases [8] , and ovariectomy exacerbates infarct volume [9] . There are an overwhelming number of studies that indicate replacement with exogenous oestrogens, both acutely and chronically, reverses the effect of ovariectomy in many different models of ischaemia (global, and permanent and transient MCAO) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The neuroprotective effects of oestrogen also extend to male rats exposed to transient MCAO [24, 25] . These findings are summarized in Table 1 . The overall message from these studies is that oestrogen can act as a potent neuroprotectant in cerebral ischaemic conditions. The literature also contains animal studies that have reported either no effect of oestrogen [11, 17, 26] , or a detrimental effect of the hormone on stroke [27] [28] [29] [30] [31] (also summarized in Table 1 ). For example, low and high doses of chronic oestrogen pre-treatment (which result in blood plasma oestrogen levels comparable with the low and high phases of the oestrus cycle respectively) exacerbated infarct size following permanent [27] [28] [29] and transient [31] MCAO in ovariectomized female rats, and a chronic low dose increased neuronal loss following 5, but not 10, min of global ischaemia in rats [30] . Oestrogen also increased infarct size after transient MCAO [32] and increased neuronal cell loss after forebrain ischaemia [33, 34] in diabetic animals. Furthermore, oestrogen has been shown to attenuate the neuroprotective effects of isoflurane pre-conditioning in mice exposed to transient MCAO [35] . These studies highlight the potential for oestrogen to have detrimental effects where there is pre-existing disease, prior exposure to anaesthetics or other pre-conditioning stimuli. Although there are currently fewer studies reporting the detrimental effects of oestrogen, the takeaway message is that the actions of oestrogen in the ischaemic brain can no longer be considered as purely beneficial and are much more complex than initially thought.
What then is the basis for the differential effects of oestrogen on the ischaemic brain? We hypothesize that it reflects the balance between a range of beneficial and detrimental effects (summarized in Figure 1 ), which will be discussed further.
Determinants of beneficial compared with detrimental oestrogenic effects
It is currently unclear what determines the balance of different effects of oestrogen in the ischaemic brain. Beneficial effects could arise from its vasodilatory properties, particularly when reperfusion occurs. Oestrogen has been shown to dilate pial vessels acutely [36, 37] and chronically [38, 39] , via the up-regulation of eNOS (endothelial NO synthase), and to improve reperfusion after ischaemia [40] [41] [42] . A variety of oestrogen-like compounds, with no receptor affinity, protect the rodent brain from stroke through antioxidant mechanisms [43] . The presence of a phenolic A ring provides the hormone with free-radical-scavenging properties [44] , enabling oestrogen to inhibit peroxide accumulation [45, 46] and lipid peroxidation [47] [48] [49] . It has also been shown to provide neuroprotection against apoptosis via transcription through the AP-1 (activator protein-1) site, downstream from JNK (c-Jun N-terminal kinase) and caspase 3 activation [50] . The anti-inflammatory effects of oestrogen are also well documented and could contribute to its neuroprotective actions [51] . ERs (oestrogen receptors) are located on immune cells (macrophages, microglia, mast cells and T-cells) and their activation decreased pro-inflammatory cytokine release in vitro [52] , which may, at least in part, explain ER-mediated neuroprotection (see the next section).
Of note, the antioxidant and anti-inflammatory effects of oestrogen may be more prominent in transient ischaemia models, since reperfusion can be associated with both free radical production and migration of inflammatory cells into the brain [53] . However, under some circumstances, oestrogen can be pro-inflammatory, particularly when there is a pre-existing inflammatory condition [54] . Oestrogen potentiated leucocyte adhesion [55] and increased pro-inflammatory mediators [32] following transient MCAO in hyperglycaemic diabetic ovariectomized rats. In rats with prolonged oestrogen deficiency, oestrogen replacement failed to suppress pro-inflammatory mediators and delaying oestrogen treatment slightly increased their levels [56] . There are a variety of other candidate mechanisms which may explain the detrimental effects of oestrogen, many of which are associated with excitotoxicity. 17β-Oestradiol has been shown to increase glutamate NMDA (N-methyld-aspartate) receptor mRNA levels in the cerebral cortex [57] , increase NMDA-binding sites in CA1 pyramidal cells [58] and increase NMDA-dependent Ca 2+ transients [59] . Oestrogen can also decrease the uptake of l-glutamate by astrocytes, which could have a knock on influence on ischaemia-induced excitotoxicity [60] . In a recent systematic review, it was proposed Diabetic OVX female mouse Increased neuronal loss [34] that the prolonged supraphysiological levels of oestrogen, released by high-dose pellet implants, was responsible for the detrimental effects of oestrogen [61] .
ER-mediated neuroprotection
There are two classical nuclear ER subtypes (ERα and ERβ), although a membrane-associated ER has also been described. However, while both ERα and ERβ
Figure 1 Potential determinants in the balance between beneficial and detrimental oestrogenic effects
subtypes have significant homology, there are differences in their brain distribution [62] . Studies using in situ hybridization indicate widespread distribution of ERβ mRNA throughout the brain, including olfactory bulbs, cerebellum and cerebral cortex [63, 64] , whereas ERα is more associated with sites related to reproductive behaviour such as the hypothalamus. Although the cerebral cortex and hippocampus contained both ER mRNAs, the hybridization signal for ERα mRNA was very weak compared with ERβ mRNA [62] . Additionally, there are differences in the structure of the ligand-binding domains [65] and gene activation profiles [66, 67] . It is therefore likely that ERα and ERβ subtypes are capable of mediating different effects; the individual contributions of each receptor subtype to neuroprotection is still under study. Selective ERα and β agonists and ER KO (knockout) mice have been used to examine the contribution of each receptor subtype in stroke. The non-selective ER antagonist ICI 182 780 increased striatal infarct volume in (non-ovariectomized) female mice exposed to transient MCAO [68] , demonstrating ER-mediated effects in stroke. Both a selective ERα agonist, PPT (propyl pyrazole triol), and a selective ERβ agonist, WAY 200070-3, protected hippocampal neurons in ovariectomized female rats exposed to global ischaemia [69] , as did the selective ERβ agonist DPN (diarylpropiolnitrile) in ovariectomized female mice [70] . However, no observable effects of DPN were detected in male rats [71] or ovariectomized females exposed to permanent MCAO [72] . Studies in KO mice have also failed to provide clearcut answers concerning the contribution of each receptor. One study showed no increase in infarct size in ERαKO compared with wild-type in non-ovariectomized females following transient MCAO [73] , which suggests no involvement of ERα in neuroprotection. However, infarct volume following permanent MCAO in another study was reduced after oestrogen treatment in ovariectomized wild-type and ERβKO mice, but not ERαKO mice, which would suggest oestrogen-induced neuroprotection in that model was dependent on ERα [74] . ERα and ERβ are also differentially expressed after injury; ERα expression increasing early and ERβ expression increasing later [75] . These studies highlight the complexities of the role of oestrogen in stroke and the need for further research into specific ischaemic conditions (type, duration and severity) that induce the up-regulation and down-regulation of these receptors.
Oestrogen as a neurotrophic agent
A significant amount of literature exists for a neurotrophic influence of chronic oestrogen treatment. LTP (long-term potentiation), a model for cellular consolidation and plasticity, is maximal during prooestrus and oestrogen replacement to ovariectomized females decreases the threshold for its induction [76, 77] . Oestrogen increases hippocampal NMDA-receptorbinding sites [78] and NMDA-receptor-mediated excitatory post-synaptic potentials [79] . Furthermore, oestrogen-induced synaptogenesis has been observed in vitro using cultured hippocampal cell populations [80] and in vivo [81] using invasive techniques. Female rats in pro-oestrus have a 30 % increase in hippocampal neuronal spine densities compared with other stages of the oestrous cycle [82, 83] . These cyclic changes can be prevented with ovariectomy and restored using oestrogen replacement [84] . Oestrogen up-regulates various proteins associated with synaptogenesis (synaptophysin, syntaxin and spinophilin) [85, 86] , but the most prevalent hypothesis regarding the mechanism of synaptogenesis is a receptor-mediated decrease in the inhibitory effects of GABA (γ -aminobutyric acid) [87] . ERα is found in inhibitory interneurons of the hippocampus [88, 89] and oestrogen transiently suppresses GABA A -mediated inhibition of CA1 pyramidal cells [90] . If inhibition is suppressed, neurons are free to generate more synapses.
Regarding the behavioural consequences of oestrogeninduced synaptogenesis, some studies show increases in behavioural performance measures in animals treated with oestrogen. For example, ovariectomized female rodents supplemented with low physiological doses of oestrogen (producing plasma oestrogen levels comparable with normal cycling levels) have enhanced performance in working memory in water escape tasks [91] [92] [93] [94] [95] . Oestrogen-mediated cognitive enhancement is also evident in other memory tasks, such as the radial arm maze [96] [97] [98] and object place and recognition tests [99] . Oestrogen treatment following neurotoxic injury in male rats can also improve learning deficits [100] . Increased hippocampal neuronal spine formation produced by two low physiological doses of oestrogen correlated with an increase in memory retention in the water maze [101] , and aged female mice given low doses of oestrogen had increased learning and memory in the water maze, which was correlated with an increase in synaptophysin staining in the hippocampus [102] . Increased numbers of dendritic spines, and pre-and post-synaptic plasticity markers, have been observed in the CA1 region of oestrogentreated ovariectomized female mice, and this is correlated with an increase in object placement memory [103] . Thus oestrogen promotes neurotrophic/plasticity mechanisms and improves behavioural performance.
Despite this, there are surprisingly few studies reporting the ability of oestrogen to promote functional recovery and even fewer include cognitive function as an outcome test after stroke. Oestrogen was able to speed up, but not enhance, recovery of function in the cylinder test (a sensorimotor task which measures forelimb asymmetry), but had no effect on a passive avoidance test (cognitive function) after transient MCAO [104] . In a permanent MCAO study, when oestrogen administration was delayed until the infarct had fully evolved (to avoid any effects on lesion size), no evidence of significant improvements in sensorimotor function, or synaptogenesis (using protein markers), was observed [105] . Oestrogen also failed to influence functional recovery in a model of intracerebral haemorrhage [106, 107] . The key message therefore is that oestrogen may be able to accelerate recovery of function but not enhance it. However, the paucity of such studies highlights a limitation in the translation of pre-clinical work to the clinic, given that functional and cognitive assessments are important outcome measures in human stroke.
SERMs
SERMs can act as oestrogen agonists or antagonists in different tissue types (reviewed in [108] [109] [110] ), depending on the conformational changes of the ER subtypes, as well as the recruitment of co-activator and/or co-repressor proteins [111] . In addition to a number of synthetic SERMs, this drug class includes phytoestrogens, which are considered natural SERMs. Beneficial effects of these drugs are apparent in pre-clinical research. The classical synthetic SERM raloxifene provides neuroprotection from kainate injury [112] , β-amyloid injury [113] and striatal dopamine depletion [114, 115] . Acute topical tamoxifen application reduces excitatory amino acid release in the cortex of male rats exposed to global ischaemia [116] , but appears to be ineffective in reducing cell loss in the hippocampus when administered chronically to ovariectomized gerbils exposed to global ischaemia [117] . However, tamoxifen has been shown to reduce infarct volume following permanent MCAO in male [118] and female rats [119] , and after transient MCAO in male rats [120] . Even though no effect on lesion size was observed, raloxifene was able to significantly improve functional outcome in an in vivo traumatic brain injury model in male rats [121] . Arzoxifene (LY353381), a raloxifene analogue with better bioavailability, was able to reduce infarct volume in the striatum of ovariectomized female rats with transient MCAO [122] . However, another novel SERM, LY362321, was unable to provide protection from transient MCAO in ovariectomized female rats [123] .
Phytoestrogens have also been shown to have neuroprotective effects in the ischaemic brain. For example, a high-soya diet significantly reduced infarct size following permanent MCAO in intact female rats [124] and following transient MCAO in male rats [125, 126] . Phytoestrogens also reduced neurological impairment after transient MCAO in male rats [125] .
CLINICAL STUDIES
Benefits and risks of HRT, oestrogen alone and SERMs in post-menopausal women
In the present review, we have covered CHD, blood lipids and venous thrombosis, as these can be aetiologically linked to stroke, and have included dementia, mild cognitive impairment and global cognitive function, as these can be related to multi-infarct dementia. Evidence exists for the potential protective effects of circulating ovarian hormones in CHD [127] , vascular disease [37, 128, 129] and stroke [130] . Some evidence from observational studies has indicated that HRT reduces the risk of cardiovascular disease and stroke in postmenopausal women [131, 132] . However, observational studies are open to bias: women who chose to take HRT may also have had healthier lifestyles. There are now approximately ten randomized placebo-controlled clinical trials that have examined the effects of HRT, oestrogen alone or the SERMs tamoxifen and raloxifene on CHD, vascular disease or stroke (reviewed in [133] ). A summary of these trials is shown in Table 2 .
HERS (Heart and Estrogen/progestin Replacement Study) examined whether oestrogen+progestin could reduce the occurrence of MI (myocardial infarction) in women with a history of CHD. A total of 2763 women (average age, 66 years) were randomly assigned to receive placebo or oestrogen+progestin. Four years later, the oestrogen+progestin group had a slightly increased risk of MI in the first year, but a nonsignificant lower incidence for the remainder of the trial [134] . This may indicate that the benefit of HRT is associated with long-term use. The results collected from HERS were analysed further to investigate the risk of stroke. Oestrogen+progestin significantly lowered plasma cholesterol, but there was no effect on the incidence or severity of stroke [135] . ESPRIT (EStrogen in the Prevention of Re-Infarction Trial) was designed to assess whether oestrogen alone could reduce the occurrence of a second MI (in 1017 women aged 50-69 years). Oestrogen alone did not influence the incidence of re-infarction, but the occurrence of stroke and vein thrombosis was slightly (but not significantly) higher [136] . The overall trend suggested that oestrogen+progestin, or oestrogen alone, produced no decrease, or little or no increase, in the risk of a secondary MI. This is supported by an observational study in post-menopausal women with a previous MI or stroke [137] . Clinical trials have also examined risk factors (atherosclerosis and blood lipid levels) associated with CHD and stroke. EPAT (Estrogen in the Prevention of Atherosclerosis Trial) was designed to observe progression rates of subclinical atherosclerosis in 222 post-menopausal women with low cholesterol and no history of cardiovascular disease. Oestrogen alone slightly reduced the progression of artery thickening [138] . The PHOREA (Post-menopausal HOrmone REplacement against Atherosclerosis) trial, conducted in 321 post-menopausal women with increased carotid artery intima-media thickness (increased risk of CHD and stroke), indicated that 17β-oestradiol+cyclic progestin was unable to slow the progression of artery thickening [139] . The benefit of oestrogen may therefore be lost where there is evidence of pre-existing conditions. The EWA (Estrogen in Women with Atherosclerosis) trial observed the lipid levels in post-menopausal women with coronary artery disease. A total of 118 women were treated with placebo or oestrogen alone, followed by tri-monthly progestin. Three months of oestrogen alone decreased triacylglycerol (triglyceride) levels, but no differences were observed at 12 months, indicating benefits of acute treatment or that progestin nullified the effect [140] . However, opposite effects were reported in women (aged 75 years or older) when treated with conjugated oestrogen+tri-monthly medroxyprogesterone. HRT was able to decrease LDL (low-density lipoprotein)-cholesterol and increase HDL (high-density lipoprotein)-cholesterol levels [141] .
With specific regard to stroke, WEST (Women's Estrogen for Stroke Trial) assessed whether oestrogen alone reduced the risk of secondary occurrence [142] . In total, 664 post-menopausal women (average age 71 years) with at least one previous cerebral ischaemic event were recruited. Three years later, the incidence of stroke recurrence was equal between the oestrogen and placebo groups, but mortality and severity symptoms were slightly worse in the oestrogen group [143] .
The WHI trial was the largest undertaking designed to examine the effects of oestrogen+progestin, or oestrogen alone, on breast cancer and the incidence of cardiovascular disease in post-menopausal women. The trial enrolled 26000 women (aged 50-79 years) and the results sent shockwaves through the research community when the oestrogen+progestin trial was concluded prematurely in 2002 due to a significantly higher incidence of stroke [144] , cardiovascular disease, venous thromboembolic disease and breast cancer in the hormone-treated group [1] . The oestrogen alone trial was terminated in 2004 after results indicated an increased risk of stroke [145] and venous thrombosis [146] in the hormone-treated group. Interestingly, a subgroup of women [WHIMS (WHI Memory Study)] [147] were also examined for dementia and cognitive function. Although there was no difference in cognitive function between the oestrogen+progestin and placebo groups [148, 149] , oestrogen alone increased the risk of mild cognitive impairments and dementia, with no effect on distribution of dementia types between vascular dementia and Alzheimer's disease [150, 151] . It has therefore been suggested that the risks of oestrogen+progestin exceed the benefits for chronic disease prevention [152] . Similar results to the WHI trial were compiled using a simulation from data in the UK GPRD (General Practice Research Database). Incidence of stroke, venous thromboembolic events and breast cancer were all increased by oestrogen, but the incidence of colorectal cancer and MI were decreased [153] . The WISDOM (Women's International Study of long Duration Oestrogen after Menopause) trial [154] examined the effects of HRT on post-menopausal women for incidence of fracture, MI, cancer, dementia, venous thromboembolism and cerebrovascular disease. Completion was scheduled for 2016 with 22300 postmenopausal women (aged 50-69 years), but the trial was stopped in 2002 following the early discontinuation of the first arm of the WHI trial. Follow-up results were consistent with the findings of the WHI trial: HRT increased the risk of cardiovascular events and thromboembolism [155] .
The design of the WHI trial and interpretation of the results are not without criticism [156] [157] [158] [159] . On average, the recruits were more overweight (increased risk of cardiovascular disease) than the recruits from the earlier observational studies. Furthermore, prior HRT use was not accounted for (74 % without and 26 % with) and the potential effects of extended periods of oestrogen deficiency may have confounded the data. Women that fell into this latter category may have experienced the progression of subclinical vascular disease and, if treatment was started after complex atheromas have developed, HRT may not slow its progression [138, 139] . Of note, however, the 50-60-year-old age group on oestrogen alone in the WHI trial had a reduced risk of MI and stroke [159] .
A meta-analysis of the randomized control trials (28 identified) has shown an association between HRT and an increased risk of stroke {OR (odds ratio), 1.29 [ The first-generation SERMs tamoxifen and raloxifene are licensed for human use. Tamoxifen is prescribed as a treatment for breast cancer [162] , but also preserves bone density [163] and lowers cholesterol [164] . However, it can promote endometrial uterine growth and is therefore associated with an increased risk of uterine cancer [165] . Raloxifene is prescribed to reduce bone loss in postmenopausal women [166, 167] , and has also been shown to reduce the risk of breast cancer [168] . To date, there are few clinical trials that have examined the effect of SERMs on the same outcome measures used in the WHI trial. The MORE (Multiple Outcomes of Raloxifene Evaluation) trial was designed to observe the effects of raloxifene treatment on the incidence of fracture in 7705 post-menopausal women (mean age, 66 years) [169] . Three years later, the study concluded that raloxifene significantly reduced the incidence of fracture, increased bone density and reduced ER-positive breast cancer [170] . In addition, there was no reported increase in the risk of stroke in the treatment group, and the drug was assessed to have a favourable risk-benefit profile when all secondary measures were analysed according to the standards laid out in the WHI trial [171] . The RUTH (Raloxifene Use for The Heart) trial was designed to test whether or not continued raloxifene use would have any effect on the risk of coronary events in 10101 post-menopausal women (over the age of 55 years) with existing, or at high risk of developing, CHD [172] . The results indicated that raloxifene treatment did not increase the risk of coronary events or stroke, although there was an increase in the incidence of fatality associated with stroke [173] . NSABP (National Surgical Adjuvant Breast and Bowel Project) was a randomized placebo-controlled trial for the study of tamoxifen in the prevention of breast cancer. The relative risks of stroke and deepvein thrombosis were increased with tamoxifen, but CHD and death remained unaffected [162] . The NSABP STAR (Study of Tamoxifen and Raloxifene) trial showed that raloxifene was associated with a lower risk of thromboembolic events than tamoxifen, but the risk of CHD and stroke were similar for both drugs [174] . Therefore, in summary, sufficient evidence now exists for a potential detrimental role of oestrogen+progestin, and oestrogen alone, on stroke incidence and outcome, whereas the impact of SERMs remains to be established.
REASONS FOR THE DISCREPANCIES BETWEEN PRE-CLINICAL AND CLINICAL STUDIES
In general, the pre-clinical literature reports the capacity of oestrogen to protect against stroke-induced brain damage, which is contradictory to the clinical results of the WHI trial and clinical meta analyses. Several explanations can be offered. (i) Clinical trials have focussed on how HRT influenced stroke incidence, whereas the majority of pre-clinical studies have focussed on stroke outcome. It is more difficult to study stroke incidence in animal models, although it would be possible, for example, to measure latency to spontaneous stroke in the SHRSP strain. (ii) A post-menopausal period of oestrogen deficiency was often present in women recruited to the trials, whereas rodents experienced little to no oestrogen deficiency in pre-clinical studies; prolonged oestrogen deficiency has been shown to diminish the neuroprotective effects of oestrogen [56] . (iii) Different HRT combinations, formulations and doses have been used in clinical studies (see Table 2 ), whereas pre-clinical work has mostly focussed on 17β-oestradiol. (iv) Most of the pre-clinical data have been generated using young healthy adult rodents. The evidence provided above highlights the need to use aged animals in a variety of ischaemic models with and without pre-existing vascular disease in order to more accurately predict the influence of oestrogenic drugs on stroke incidence and outcome. In addition, very few, if any, studies have investigated the influence of oestrogen on cerebral ischaemia and cardiovascular disease in higher-order species. (v) There is a reduced quality and stringency of pre-clinical research compared with clinical research. A systematic review of oestrogen in preclinical stroke studies found that papers with the highest quality scores reported the lowest oestrogen efficacy [6] . Of the 27 publications detailed and scored for quality, according to the STAIR (Stroke Therapy Academic Industry Roundtable) criteria [175] , most scored only 1-4 points out of a possible 8. The STAIR scoring system allocates one point for each of the following eight criteria: (i) a dose-response relationship investigated; (ii) inclusion of randomization in the study design; (iii) determination of the optimal time window of the treatment investigated; (iv) monitoring of physiological parameters; (v) blinded outcome assessment; (vi) assessment of at least two measures of outcome (e.g. infarct size and sensorimotor function); (vii) outcome assessment in the acute phase (1-3 days); and (viii) outcome assessment in the chronic phase (7-30 days). The main reasons for low scores were a lack of a reported dose-response relationship, randomization, blinding or determination of an optimal time window. However, even when the STAIR criteria have been fulfilled, it is no guarantee that a drug will show efficacy in humans. For example, the freeradical scavenger NXY059, which passed the STAIR criteria, failed in subsequent clinical trials [176] , although it later emerged that NXY059 had poor bloodbrain barrier penetrability. (vi) Pre-clinical data have emerged which demonstrate a lack of effect, or a detrimental effect, of oestrogen on stroke outcome. Detrimental effects of oestrogen are more commonly reported in models of permanent MCAO (Table 1) , which may point to the detrimental influence of oestrogen being linked to ischaemia (and excitotoxicity), while the beneficial influences (e.g. antioxidant and vasodilatory) may have their greatest influence during the reperfusion phase of ischaemia. Arguably, more prominence should have been given to studies that reported a detrimental effect, and it is possible some neutral or negative studies failed to appear in the literature because of publication bias. Perhaps the pleiotropicity of the hormone, as well as the complex aetiology of stroke itself, explains the diversity of outcomes reported.
CONCLUSIONS
Clearly, more research is required to fully elucidate the mechanisms which promote the beneficial and detrimental effects of oestrogen. However, the future for exploitation of beneficial oestrogenic effects may lie with the unique pharmacology of SERMs and whether a bespoke SERM can be designed to selectively promote the potential of oestrogen for brain protection and repair. It is also clear that more stringent evidence from pre-clinical research will be required to effectively predict the potential for such a drug to translate to the clinic. 
